

FR0I543

HEALTH RESOURCE USE AND COST-OF-ILLNESS OF SYMPTOMATIC KNEE AND/OR HIP OSTEOARTHRITIS: DATA FROM KHOALA COHORT

J.H. Salmon1,2, A.C. Rat3,6, H. Achit4, W. Nguyen Sime5, C. Gard6, F. Guillémín4,6, D. Jolly2,7, B. Fauref8,9, R. Rheumatology, Maison Blanche Hospital, Reims University Hospitals; 2University of Reims Champagne-Ardenne, Faculty of Medicine, EA 3797, Reims; 3Rheumatology, CHU de Nancy, Hôpital de Brabois; 4Université de lorraine, EA 4360 Apermac, Nancy; 5Pharmacy, Pitié-Salpêtrière Hospital, Paris; 6INSERM, CHRU Nancy, CIC 1433 Épidémiologie clinique, Nancy, 7Research and Innovation, Robert Debré Hospital, Reims; 8Rheumatology, Université Pierre et Marie Curie Curie, 9GRC08, Institut Pierre Louis de l’Épidémiologie et Santé Publique, Pitié-Salpêtrière Hospital, Paris, France

Background: Hip and knee Osteoarthritis are a major public health problem. Data on the economic impact are scarce.

Objectives: The purpose of our study was to estimate the annual direct costs of patients followed for hip and/or knee osteoarthritis from the KHOALA cohort.

Methods: The KHOALA cohort is a French population-based multicenter cohort of 878 patients with symptomatic knee and/or hip OA, aged between 40 and 75 years old recruited between 2007 and 2009. Direct costs were collected annually.

Results: The purpose of our study was to estimate the annual direct costs of patients followed for hip and/or knee osteoarthritis from the KHOALA cohort. Costs increased with older age, female sex, retirement, a high BMI, a high Charlson index and poor health status.

Conclusions: These data are important results to describe the cost of care consumption of a sample of patients with symptomatic osteoarthritis of the hip and/or knee recruited to the general population in France. However, the specific cost attributable to osteoarthritis needs to be studied.

REFERENCE:

Disclosure of Interest: None declared


FR0I544

URINARY 6-SULFATOXYMELATONIN EXCRETION AND GALECTIN-3 Plasma Level in Patients with Osteoarthritis

K. Zaikova, O. Gumieniuk, M. Starjalovych. The Department of the Internal Medicine, National Pirogov Memorial Medical University, Vinnytsya, Ukraine

Background: Melatonin and galectin-3 are considered as factors in the development of immune-inflammatory and destructive changes in joints.1–3 Melatonin has chondrogenic and antiinflammatory properties,2–4 while galectin-3 plays an important role in cell-cell interaction, macrophage activation, angiogenesis, and apoptosis.1–3 The clinical and pathogenic significance of melatonin and galectin-3 in osteoarthritis remains on the discussion.

Objectives: To study the excretion of 6-sulftatoxymelatonin (metabolite of melatonin) and galectin-3 level in the blood and evaluate their association with the clinical manifestation and quality of life in patients with OA.

Methods: Study involved 141 patients with OA of knee joints (76.6% women), aged 58.4±9.1 years, duration of the disease 10.5±6.5 years (Me(SD)). 47 (33.3%) patients had knee and hip OA, 38 (27%) patients had reactive synovitis. The control group was presented by 36 practically healthy subjects (72.2% female) aged 57.1±9.95 years (Me(SD)). 6-sulfatoxymelatonin (6-SMT) in urine and galectin-3 in blood were determined by ELISA. The severity of pain, stiffness, and physical functioning of the joints were evaluated by the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). Quality of life was evaluated by Short Form-36 (SF-36).

Results: It was established in patients with OA a decrease in 6-SMT excretion, (mean 25.3±38.6 ng/ml in control, p<0.001) 6-SMT excretion correlated with age (r=−0.40; p=0.001) and was more significant in patients with knee and/or hip OA (mean 26.5 vs 23.0 ng/ml in patients with OA of the knee only, p<0.001). Lower levels of 6-SMT excretion associated with higher pain and with lower quality of life. Patients with OA had increased galectin-3 levels in the blood (mean 16.4±10.1 ng/ml) in the control, p<0.001. In patients with OA of knee and hip joints were estimated higher levels of galectin-3. Levels of galectin-3 were significantly higher in patients with synovitis (mean 21.5 vs. 13.8 ng/ml without synovitis, p<0.001). The increase of galectin-3 in the blood was associated with a marked increase of the total WOMAC index and with decrease of life quality. The level of galectin-3 directly correlated with age, disease duration (r=0.28, 0.23, p<0.01) and inversely correlated with 6-SMT excretion (r=−0.28; p<0.01).

Conclusions: Lower levels of melatonin and higher level of galectin-3 were associated with higher WOMAC index and poorer quality of life in patients with OA. This association may reflect possible pathogenic role of melatonin and galectin-3 in OA.

REFERENCES:

Disclosure of Interest: None declared


FR0I545

RISK FACTORS PREDICTING RADILOGICAL PROGRESSION OF KNEE OSTEOARTHRITIS

I. Alekseeva1, S. Ankin1, N. Kashevskaya1, E. Sharapova1, E. Taskina1, T. Korotkova1, T. Raskina2, E. Ottova1, A. Dubkova1, E. Zonova1, I. Vingogradova1, 1FSBI V.A. Nasonova Research Institute of Rheumatology, Moscow, 2: FSBEI HE Komsomol MOH, Kemerovo, 2: Regional SBHH CDC MOH Khabarovsk krayskii, Khabarovsk, 4Pacific State Medical University, Vladivostok. 5: FSBEI HE Novosibirsk State Medical University, MOH, Novosibirsk; 6: SH Ulyanovsk regional affiliated hospital, Ulyanovsk, Russian Federation

Background: Currently a number of risk factors (RF) are considered to be responsible for radiological progression of knee osteoarthritis (OA), nevertheless key predictors of OA progression have not yet been established.

Objectives: To identify RF predicting radiological progression of knee joint osteoarthritis (OA) in a 5 year multicenter prospective study.

Methods: This study of RF predicting knee OA progression was the first with multicenter prospective design ever conducted in Russia. The study included 344 female patients 40–75 y.o with primary stage I-II knee OA (ACR criteria) from 6 centres. Radiological stage was identified by Kellgren J. Lawrence J. grading